English | 繁體

Search in the results

UM

Browse/Search Results:  1-3 of 3 Help

Selected(0)Clear Items/Page:    Sort:
Characteristics of clinical trials of new oncology drugs approved in China Journal article
Yang, Jing, Yang, Ji, Hu, Yuan Jia. Characteristics of clinical trials of new oncology drugs approved in China[J]. Cancer, 2024, 130(5), 671-682.
Authors:  Yang, Jing;  Yang, Ji;  Hu, Yuan Jia
Favorite | TC[WOS]:2 TC[Scopus]:2  IF:6.1/6.7 | Submit date：2024/05/16
Clinical Evidence  Drug Lag  Novel Anticancer Drugs  Pivotal Clinical Trials  Programmed Death-1 (Pd-1) Inhibitors  Programmed Death-ligand 1 (Pd-l1) Inhibitors  
Characteristics of clinical trials of new oncology drugs approved in China Review article
2023
Authors:  Jing Yang;  Ji Yang;  HU YUANJIA
Adobe PDF | Favorite | TC[WOS]:2 TC[Scopus]:2  IF:6.1/6.7 | Submit date：2024/01/02
Clinical Evidence  Drug Lag  Novel Anticancer Drugs  Pivotal Clinical Trials  Programmed Death-1 (Pd-1) Inhibitors  Programmed Death-ligand 1 (Pd-l1) Inhibitors  
Research and development of mAb drugs in China: a look from policy perspectives Journal article
Rong Jiang, Yuanyuan Sun, Carolina Ung, Xinyue Dong, Xiangjun Kong, Yuanjia Hu, Rong Shao. Research and development of mAb drugs in China: a look from policy perspectives[J]. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2019, 15(11), 2695-2705.
Authors:  Rong Jiang;  Yuanyuan Sun;  Carolina Ung;  Xinyue Dong;  Xiangjun Kong; et al.
Favorite | TC[WOS]:3 TC[Scopus]:4  IF:4.1/4.2 | Submit date：2020/03/12
r&d Support And Guidance Policy  Clinical Trial Policy  Drug Lag  Innovation Support System  Mab Drugs  Marketing Approval Policy